

Diary No: 3370  
Date: 30.01.2018

Tele No.011-23236965  
Fax.No.011-23236973

**F. No 12-30/15-DC (Pt. B)**  
**Government of India**  
**Directorate General of Health Services**  
**Central Drugs Standard Control Organization**  
**FDA Bhawan, New Delhi – 110002 (India)**  
**New Drugs Division**

Dated: 01 OCT 2018

To

M/s. Pharmazz India Private Ltd.,  
H-6, Site-C, Surajpur Industrial Area,  
Greater Noida-201 307 (UP).

**Subject:** Permission for conducting clinical study entitled, "A Prospective, Multicentric, Randomized, Double Blind, Saline Controlled Phase II Clinical Study to Compare the Safety and Efficacy of PMZ-1620 Therapy along with Standard Supportive Care in Patients of Acute Spinal Cord Injury"- regarding.

**CT NOC No. CT/ND/18/2018**

**Reference:** Your application no. PMZ-1620/SCI/IND/01/2018 dated 30.01.2018 on the subject mentioned above.

Sir,

This Directorate has no objection to your conducting the subject mentioned clinical trial as per the provisions of Drugs & Cosmetics Rules under supervision of the following investigator and as per the **Protocol No: PMZ-1620/CLINICAL-2.3/2018, Version No: 2.0, Dated 05.07.2018** submitted to this Directorate.

S. No	Investigator and Trial site	Ethics Committee Name and Registration Number
1.	<b>Dr. Saurabh Singh,</b> Department of Orthopedics, Institute of Medical Science, Banaras Hindu University Varanasi, 221 005 UP.	Institutional Ethics Committee, Institute of Medical Sciences, Banaras Hindu University, Varanasi-221 005, Uttar Pradesh <b>ECR/526/Inst/UP/2014/RR-2017</b>
2.	<b>Dr. Nilesh Agrawal,</b> New Era Hospital, Queta Colony, Near Telephone Exchange square, Central Avenue Road, Nagpur-440 008, Maharashtra, India.	Ethics Committee, New Era Hospital, Central Avenue Road, New Telephone Exchange Chowk, Queta Colony, Near Jalaram Mandir, Nagpur-440 008, Maharashtra, India <b>ECR/896/Inst/MH/2016</b>
3.	<b>Dr. Harvinder Singh Chhabra,</b> Indian Spinal Injuries Centre, Sector-C, Vasant Kunj, New Delhi-110 070.	Institutional Ethics Committee, Indian Spinal Injuries Centre (ISIC), Sector – C, Vasant Kunj, New Delhi-110 070, India <b>ECR/96/Inst/DL/2013/RR-16</b>

**Kindly note that the clinical trial permission is subject to the following conditions:-**

- a) Clinical trial shall be conducted in compliance with the approved protocols, requirements of Schedule Y, Good Clinical Practice Guidelines issued by this Directorate and other applicable regulations.
- b) Approval of Institutional Ethics Committee duly registered with CDSCO (under Rule 122DD of Drugs & Cosmetics Rules) should be obtained and submitted to this Directorate before initiation of the study.
- c) Clinical trials shall be registered at Clinical trials Registry of India before enrolling the first patient for the study.
- d) Annual status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Licensing Authority, and in case of termination of any clinical trial the detailed reasons for the same shall be communicated to the said Licensing Authority.
- e) Any report of serious adverse event occurring during clinical trial study to the subject, after due analysis, shall be forwarded within fourteen days of its occurrence as per Appendix XI and in compliance with the procedures prescribed in Schedule Y.
- f) In case of an injury or death during the study to the subjects, the applicant shall provide complete medical management and compensation in the case of trial related injury or death in accordance with rule 122 DAB and the procedures prescribed under Schedule Y, and the details of compensation provided in such cases shall be intimated to the Licensing Authority within thirty days of the receipt of the order of the said authority.
- g) The premises of Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial study sites shall be open to inspection by the officers authorized by the Central Drugs Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to verify compliance to the requirements of Schedule Y, Good Clinical Practices guidelines for conduct of clinical trial in India and other applicable regulations.
- h) The Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial study sites and the Investigator shall allow officers authorized by the Central Drugs Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to enter with or without prior notice, any premises of Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial sites to inspect, search and seize any record, data, document, books, investigational drugs, etc. related to clinical trial and provide adequate replies to any queries raised by the inspecting authority in relation to the conduct of clinical trial.
- i) Clinical trial shall be conducted only at those sites which are institutes/hospitals having adequate emergency facilities and duly registered Institutional Ethics committees.

- j) The sponsor shall ensure that the number of clinical trials an investigator can undertake should be commensurate with the nature of the trial, facility available with the Investigator etc.
- k) The details of payment/honorarium/financial support/fees paid by the Sponsor to the Investigator(s) for conducting the study shall be made available to this directorate before initiation of each of the trial sites.
- l) In addition to the requirement of obtaining written informed consent, an audio-video recording of the informed consent process in case of vulnerable subjects in clinical trial of New Chemical Entity or New Molecular Entity including procedure of providing information to the subject and his understanding on such consent, shall be maintained by the investigator for record; provided that in case of clinical trial of anti-HIV and anti-leprosy drugs, only audio recording of the informed consent process of individual subject including the procedure of providing information to the subject and his understanding on such consent shall be maintained by the investigator for record, as per Government of India, Gazette Notification vide G. S. R. no. 611(E) dated 31.07.2015.
- m) The bulk drug to be used in manufacturing of finished formulation intended to be used in the clinical trial and clinical trial batches of finished formulation shall be manufactured under GMP conditions using validated procedures and shall have ongoing stability programme.
- n) If the clinical trial batches are different from that of the primary batches for which data have been submitted, stability reports for clinical trial batches are to be submitted as per Appendix IX of schedule Y of drugs and Cosmetics Rules for Drug substances and formulation along with Clinical study Report.
- o) It may kindly be noted that merely granting permission to conduct clinical trials with the drug does not convey or imply that based on the clinical trial data generated with the drug, permission to market this drug in the country will automatically be granted to you.
- p) Informed consent documents (ICD) viz. Patient Information sheet (PIS) and Informed Consent form (ICF) complete in all respect as per the requirements specified in Appendix V of Schedule Y of the Drugs and cosmetics Rules, 1945 must got approved from the respective Ethics Committee and Submitted to CDSCO before enrolling first subject at the respective site.
- q) **First 8 patients should be evaluated at 15 days also.**
- r) **Include those sites which have fairly common standard of care for patients of acute spinal cord injury.**
- s) **The informed consenting through LAR should be discussed and decided by the respective Ethics Committee.**

Yours faithfully,



(Dr. S. Eswara Reddy)  
Drugs Controller General (India)

